Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial

Smyth, EC, Rowley, S, Cafferty, FH et al. (17 more authors) (2019) Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial. JAMA Oncology, 5 (8). pp. 1181-1187. ISSN 2374-2437

Abstract

Metadata

Authors/Creators:
  • Smyth, EC
  • Rowley, S
  • Cafferty, FH
  • Allum, W
  • Grabsch, HI
  • Stenning, S
  • Wotherspoon, A
  • Alderson, D
  • Crosby, T
  • Mansoor, W
  • Waters, JS
  • Neville-Webbe, H
  • Darby, S
  • Dent, J
  • Seymour, M https://orcid.org/0000-0002-2441-9629
  • Thompson, J
  • Sothi, S
  • Blazeby, J
  • Langley, RE
  • Cunningham, D
Copyright, Publisher and Additional Information: © 2019 Smyth EC et al. This is an open access article distributed under the terms of the CC-BY License.
Dates:
  • Published: 20 June 2019
  • Accepted: 28 March 2019
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 27 Jun 2019 08:45
Last Modified: 14 Aug 2019 12:53
Status: Published
Publisher: American Medical Association
Identification Number: https://doi.org/10.1001/jamaoncol.2019.1179
Related URLs:

Share / Export

Statistics